Forum Health Launches Groundbreaking AI Technology to Detect Signs of Heart Disease at an Earlier Stage

Forum Health Fond du Lac, a Forum Health national integrative and functional medicine network, has launched the Multifunction Cardiogram™ (MCG™) scan for early detection of heart disease and cardiac abnormalities.

Phil Hagerman, Forum Health CEO: “Our vision is to use advanced technologies like AI in everything we do. The MCG™ scan uses AI to identify potential heart issues before they escalate into life-threatening conditions. Fond du Lac is the first clinic in our network to launch this technology with great success and we plan to expand it to other clinics.”

The MCG™ scan is a preventative measure that can be used in youth and general populations that are increasingly at risk of heart-related disease. Unlike traditional methods that rely on the onset of symptoms, the MCG™ scan uses advanced artificial intelligence (AI) technology to identify a wide range of cardiac concerns, including:

-Coronary artery disease
-Myocarditis
-Microvascular disease
-Rhythm disturbances
-Heart stiffening
-Plaque instabilities
-Occlusions with high sensitivity

Dr. Steven Meress, Forum Health Fond du Lac: “The MCG™ scan is a revolutionary cardiac device. In March 2023, we performed the first round of scans; five months later, 12 out of 12 follow-up scans show improvement. This evidence shows how effective early interventions can be when based off the MCG™ scan and the positive impact on cardiac health.”

The Multifunction Cardiogram™ scan is powered by AI-driven technology, which continuously learns and improves with each test conducted. Each scan is compared to a robust database of more than 200,000 patients with established cardiovascular disease and assigned an objective heart dysfunctional burden score. This score ranks the patient’s heart health, empowering physicians to make informed decisions and develop personalized treatment plans.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”
Exit mobile version